Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Condition:   Hidradenitis Suppurativa Interventions:   Drug: CFZ533;   Drug: Placebo to CFZ533;   Drug: LYS006;   Drug: Placebo to LYS006 Sponsor:   Novartis Pharmaceuticals Not yet recruiting

Source: ClinicalTrials.gov - February 1, 2019 Category: Research Source Type: clinical trials